|
|
|
Dear [Recipient’s name]
|
|
Were you able to watch our industry program about the latest innovations in pulmonary arterial hypertension (PAH)? If you missed our industry
program on August 6 at ATS 2020 Virtual, you still have a chance to learn more about sotatercept, our investigational drug candidate.
Sotatercept is a new investigational therapy in testing that may change the course of PAH progression by rebalancing BMPR-II signaling.
Find out how by viewing the full presentation—now available on the ATS 2020 virtual platform until November 10.
|
|
A New Direction in PAH:
|
|
A Potential Therapy for Rebalancing BMPR-II Signaling
|
|
|
|
Featuring Vallerie McLaughlin, MD, University of Michigan, Ann Arbor
|
|
Topic overview
|
|
Despite multiple treatment options, patients with PAH still face a devastating and progressive disease.
This program will focus on the imbalances in BMPR-II and activin receptor signaling that may drive PAH progression.
A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential
disease modification.
|
|
|
|
This is an Industry Program at the ATS 2020 Virtual Conference. This presentation is sponsored by Acceleron Pharma and is open to all ATS 2020 Virtual attendees.
|
|
|
|
|
Acceleron is passionate about accelerating the discovery of novel therapies that can help patients with PAH and other rare diseases. We hope you find this presentation helpful as we look to the future of PAH therapy.
|
|
If you have any questions about our clinical trials, eligibility, enrollment, or our pulmonary pipeline, feel free to contact us at 617-649-9200.
|
|
|
|